N-乙酰转移酶10、丝氨酸羟甲基转移酶 2、YTHN6-甲基腺苷RNA结合蛋白1在肺癌组织中的表达及与临床病理特征、预后的相关性

doi:10.3969/j.issn.1005-6483.20241104

摘要/Abstract

摘要： 目的探讨N-乙酰转移酶10(NAT10)、丝氨酸羟甲基转移酶 2(SHMT2)、YTHN6-甲基腺苷RNA结合蛋白1(YTHDF1)在肺癌组织中的表达及与临床病理特征、预后的相关性。方法 2020年4月~2021年4月收治的肺癌病人98例，收集病人术中切除的癌组织及癌旁组织，采用免疫组化法检测NAT10、SHMT2、YTHDF1表达水平。随访3年，根据病人预后情况分为存活组与死亡组，比较两组一般临床病理特征资料，分析NAT10、SHMT2、YTHDF1与病人预后的关系。采用多因素Cox回归分析肺癌病人预后的影响因素。结果 NAT10、SHMT2、YTHDF1在癌组织中的高表达比例显著高于癌旁组织，差异有统计学意义(P＜0.05)；NAT10、YTHDF1表达与临床分期、分化程度以及淋巴结转移有关(P＜0.05)，SHMT2表达与临床分期、分化程度、肿瘤直径以及淋巴结转移有关(P＜0.05)；存活组与死亡组的肿瘤直径、临床分期、分化程度、淋巴结转移以及NAT10、SHMT2、YTHDF1表达比较，差异有统计学意义(P＜0.05)；NAT10、SHMT2、YTHDF1高表达病人生存率显著低于低表达病人(χ2=6.354，P=0.012，χ2=8.512，P=0.004，χ2=4.791，P=0.029)；淋巴结转移、NAT10、SHMT2、YTHDF1高表达均为影响病人预后的危险因素(P＜0.05)。结论肺癌组织中NAT10、SHMT2、YTHDF1均为高表达，与临床病理特征及预后具有一定相关性，可作为肺癌病人预后的相关评估指标。

关键词: N-乙酰转移酶10, 丝氨酸羟甲基转移酶 2, YTHN6-甲基腺苷RNA结合蛋白1, 肺癌, 临床分期, 预后

Abstract: Objective To investigate the expression of N-acetyltransferase 10 (NAT10),serine hydroxymethyltransferase 2 (SHMT2) and YTH domain family protein 1 (YTHDF1) in lung cancer tissues and their correlation with clinicopathological characteristics and prognosis. Methods A total of 98 lung cancer patients admitted to our hospital from April 2020 to April 2021 were regarded as the observation subjects.The cancerous tissues and adjacent tissues of the patient during surgery were collected.Immunohistochemistry was used to detect the expression levels of NAT10,SHMT2 and YTHDF1.The patients were followed up for 3 years and divided into the survival group and the death group according to their prognosis.The data of general clinicopathological characteristics were collected and analyzed.The relationship between NAT10,SHMT2 and YTHDF1 with the prognosis of patients were analyzed.Multivariate Cox- regression was used to analyze the influencing factors of lung cancer patients.Results The high expression ratios of NAT10,SHMT2 and YTHDF1 in cancer tissues were obviously higher than those in adjacent tissues (P<0.05).The expression of NAT10 and YTHDF1 was related to clinical stage,degree of differentiation and lymph node metastasis (P<0.05),and the expression of SHMT2 was correlated with clinical stage,degree of differentiation,tumor diameter,and lymph node metastasis (P<0.05).There were statistically significant differences in tumor diameter, clinical stage, degree of differentiation, lymph node metastasis, and expressions of NAT10, SHMT2, and YTHDF1 between the survival group and the death group (P<0.05). NAT10, SHMT2, YTHDF1 patient survival rates significantly below the low of high expression patients (χ2=6.354, P=0.012, χ 2 =8.512, P=0.004, χ2=4.791, P=0.029).Lymph node metastasis, high expression of NAT10, SHMT2 and YTHDF1 are all risk factors affecting the prognosis of patients (P < 0.05 ).Conclusion NAT10,SHMT2,and YTHDF1 are all highly expressed in the tissues of lung cancer,and have a certain correlation with clinical pathological characteristics and prognosis.They may serve as relevant evaluation indicators for the prognosis of lung cancer patients.

Key words: N-acetyltransferase 10, serine hydroxymethyltransferase 2, YTH domain family protein 1, lung cancer, clinical staging, prognosis

黄志刚张兴伟张宇邹青旭. N-乙酰转移酶10、丝氨酸羟甲基转移酶 2、YTHN6-甲基腺苷RNA结合蛋白1在肺癌组织中的表达及与临床病理特征、预后的相关性[J]. 临床外科杂志, 2025, 33(8): 827-831.

HUANG Zhigang, ZHANG Xingwei, ZHANG Yu, ZOU Qingxu. The expression of N-acetyltransferase 10,serine hydroxymethyltransferase 2,YTH domain family protein 1 in lung cancer tissues and their correlation with clinicopathological characteristics and prognosis[J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(8): 827-831.

参考文献

相关文章 15

[1]	徐瑞鑫王浩力张文伟边洪春. 三维电视胸腔镜肺段切除术采用吲哚菁绿荧光反染法治疗Ⅰ期肺癌病人的疗效及安全性观察[J]. 临床外科杂志, 2025, 33(8): 822-826.
[2]	汪俊吕瑕智陶玉胡传朋. 血清微小核糖核酸-335-5p、内皮细胞特异性分子-1对食管癌病人的早期诊断及预后评估价值[J]. 临床外科杂志, 2025, 33(8): 836-840.
[3]	牛磊霍承瑜刘宗志. 纤维蛋白原与白蛋白比值、预后营养指数、系统性免疫炎症指数与肺癌胸腔镜肺叶切除术病人预后关系的研究[J]. 临床外科杂志, 2025, 33(7): 708-.
[4]	梁志伟辛鑫余会敏. 长链非编码RNA GAS5和基质金属蛋白酶9在非小细胞肺癌病人血清中的表达及临床价值[J]. 临床外科杂志, 2025, 33(5): 498-502.
[5]	仇睿刘阳马波吕志平马云帆. 切除修复交叉互补族6-样表达与非小细胞肺癌临床病理特征的关系及其预后意义[J]. 临床外科杂志, 2025, 33(3): 266-270.
[6]	龚顺松朱炎董轼蔡奕欣. 非小细胞肺癌中PROM2、RALY 和Rab15表达及预测发生骨转移的价值研究[J]. 临床外科杂志, 2025, 33(3): 271-274.
[7]	彭蓉蓉, 卞家蓉, 谈王蓉. 血清神经元特异性烯醇化酶、基质细胞衍生因子1和诱饵受体3联合在非小细胞肺癌病人预后评估中的临床意义[J]. 临床外科杂志, 2025, 33(1): 92-96.
[8]	赵洁江帆祁涛闫丽娟简鸽刘梦婷. 非小细胞肺癌表皮生长因子受体靶向治疗后病人血清微小RNA-30a-5p和微小RNA-129-5p表达与疗效的关系[J]. 临床外科杂志, 2024, 32(9): 923-926.
[9]	王洪昌杨晓波王海永张兴和孙磊. 十二指肠-肺双原发癌一例[J]. 临床外科杂志, 2024, 32(9): 1003-1004.
[10]	于乐涛夏国庆尹玉良. 三种不同自控镇痛方案对胸腔镜下肺癌手术治疗病人镇静镇痛的影响[J]. 临床外科杂志, 2024, 32(8): 882-886.
[11]	黄如敬鲁洪岭吴超杨洪娟尹晓明赵阳康华薇田菲孙云川. 非小细胞肺癌病人血清miR-326和miR-623表达与临床病理特征及预后的关系[J]. 临床外科杂志, 2024, 32(7): 706-710.
[12]	刘玉婷文进秋侯彦深郭明珊艾孜买提·艾尼瓦尔热孜亚·艾尔肯张冰. 右美托咪定复合舒芬太尼病人自控静脉镇痛对胸腔镜下肺癌根治术病人术后免疫功能及呼吸功能恢复的影响[J]. 临床外科杂志, 2024, 32(7): 767-771.
[13]	高超戴希勇蒋钰辉刘小玉李晶熊浩. 非小细胞肺癌病人血清中miR-455、miR-383表达水平及其临床诊断价值分析[J]. 临床外科杂志, 2024, 32(6): 607-610.
[14]	万伟张彬刘勇志井淼王晓栋. 胸腔镜下肺叶切除、解剖性肺段切除、肺楔形切除治疗非小细胞肺癌的疗效分析[J]. 临床外科杂志, 2024, 32(3): 266-270.
[15]	苏政军黄珊珊陈万进. 血清纤维胶凝蛋白3、胶原三股螺旋重复蛋白1对非小细胞肺癌的诊断价值及与临床病理特征的关系[J]. 临床外科杂志, 2024, 32(2): 164-167.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed